## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.98 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-11.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($975.88)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker**
- Source: ts2.tech | 20251202T152249 | Bullish | Relevance: 100%
- Eli Lilly's stock is trading near record highs due to the success of its obesity and diabetes drugs, particularly Zepbound and Mounjaro. Recent price cuts for Zepbound and a strong Q3 2025 earnings report have reshaped its outlook, alongside a significant push with its Alzheimer's drug Kisunla and an oral GLP-1 candidate, orforglipron. The company faces both continued growth opportunities and risks related to pricing pressure, competition, and its high valuation.

**2. Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034**
- Source: GlobeNewswire | 20251202T041000 | Bullish | Relevance: 100%
- The abemaciclib market, dominated by Eli Lilly and Company, is projected to grow from $1.6 billion in 2025 to $2.54 billion by 2029, driven by increasing breast cancer incidence, advancements in combination therapies, and integration of personalized medicine. Key market opportunities include targeted therapies in oncology, immuno-oncology combinations, and expanded access to cancer treatment in emerging markets. North America was the largest market in 2024, with Asia-Pacific expected to be the fastest-growing region.

**3. Eli Lilly Slashes Prices of Popular Weight-Loss Drug Zepbound**
- Source: NTD News | 20251201T203609 | Somewhat-Bullish | Relevance: 100%
- Eli Lilly announced significant price reductions for its weight-loss drug, Zepbound, making it more affordable for patients purchasing through LillyDirect. The price cuts aim to increase accessibility to obesity treatments, especially as the company experiences financial success and federal initiatives push for broader drug price reductions. These moves are expected to influence the wider healthcare system and private insurance costs.

**4. Eli Lilly Becomes First Trillion-Dollar Health Company**
- Source: Clinical Pain Advisor | 20251201T153609 | Bullish | Relevance: 100%
- Eli Lilly has become the first healthcare company globally to achieve a $1 trillion market value, driven largely by the success of its diabetes drug Mounjaro and weight-loss drug Zepbound. The company's stock has surged over 36% this year due to rising demand for its treatments, with Mounjaro and Zepbound generating billions in sales. Eli Lilly anticipates continued growth through expanded insurance coverage, new approvals, and the planned release of an oral weight-loss drug.

**5. Eli Lilly cuts Zepbound price to widen access for obesity drug**
- Source: Reuters | 20251201T130200 | Bullish | Relevance: 100%
- Eli Lilly has reduced the price of its popular obesity drug Zepbound to improve affordability and access for U.S. patients amidst surging demand for weight-loss therapies. The price cuts affect single-dose vials and follow similar reductions for multi-dose pens, which are awaiting FDA approval. This strategic move aims to address cost and coverage barriers, further solidifying Lilly's position in the rapidly expanding obesity drug market.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 10, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |
| 2025-11-19 | Truist Securiti | $1182 | $1038 | +14% |
| 2025-11-18 | JP Morgan | $1150 | $1050 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |
| 2025-11-19 | Truist Securiti | main | Buy |
| 2025-11-18 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-11.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $18559M sold (28 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 10 raises (avg +17%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 31.7x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (10 raises, avg +17%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $966.2B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 31.7 |
| Current P/E | 43.7 |
| YoY Growth | 37.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 10.7% to -1.1% (-11.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.1pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-7.04), momentum weakening. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.09% (CS: 41) | Neutral |
| RSI_14 | 60.4 | Neutral |
| MACD Histogram | -7.04 | Bearish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.148x | Above |
| vs SMA200 | 1.275x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1033.56
- **Stop Loss:** $975.88 (5.6% risk)
- **Target:** $1148.92 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $16,536.96
- **Portfolio %:** 16.54%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*